Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis (OCT in MS)
Recruitment status was: Active, not recruiting
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Using OCT to Capture Retinal Microvascular Changes Associated With MS|
- Number of patients with MS who also have reduced blood flow in the retina and/or changes in the blood flow to the retina compared to healthy subjects [ Time Frame: 1 year ]
- Number of patients with MS who have different blood flow response than healthy subjects to visually stimulating patterns. [ Time Frame: 1 year ]
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||June 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Multiple Sclerosis Patients
Physician-confirmed diagnosis of multiple sclerosis. Any subtype is acceptable. For example, relapsing-remitting, secondary progressive, primary progressive
Healthy Normal Subjects
Volunteers with healthy eyes.
Background data including age, sex, medical history, and neurologic history and status will be gathered prior to the study/OCT testing visit. At the single study/testing visit, subjects will have their blood pressure and intraocular pressure checked (using numbing drops that last 15-20 minutes), undergo vision testing and then have their eyes dilated with standard dilating drops. They will then undergo optical coherence tomography testing to determine the blood flow of the retinal blood vessels and to take other measurements of the back of the eye including thicknesses of the nervous tissue elements of the retina.
OCT Procedure: The subject will be seated and have their head positioned on a chin rest. They will be asked to look at a target (a lighted spot) while a beam of light scans the front part of the eye. The light is infrared and will not be visible or cause any sensation. A cotton tip swab may be used to help hold the eyelid open temporarily if necessary.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01596881
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Rebecca Spain, MD, MSPH||Oregon Health & Science Universtiy|